

Supplementary Information

An efficient sodium chloride-catalyzed synthesis of bis(indolyl) methanes in green solvent and their antibacterial evaluation

Lensayula Longkumer^a, Putusenla Imchen^a, Betokali K Zhimomi^a, Toka Swu^b, I Tavishe Phucho^{a,*}

^aDepartment of Chemistry, Nagaland University, Lumami 798 627, Nagaland, India

^bDepartment of Chemistry, Pondicherry University, Kalapet, Puducherry 605 014, India

*E-mail: itphucho@nagalanduniversity.ac.in

Received 14 April 2021; accepted (revised) 22 August 2022

S. No.	Contents	Pg. No.
1	Fig. S1 — Antibacterial activity of compound (a) 1, 2, 3, 4; (b) 5, 6, 7, 8 and (c) 9, 10, 11, +ve control against <i>Bacillus subtilis</i> (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)	2
2	Fig. S2 — Antibacterial activity of compound (a) 1, 2; (b) 3, 4; (c) 5, 6; (d) 7,8; (e) 9, 10, 11 and +ve control against <i>Escherichia coli</i> (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)	2
3	Fig. S3 — Antibacterial activity of compound (a) 1,2,3,4; (b) 5, 6, 7, 8 and (c) 9, 10, 11 +ve control against <i>Klebsiella pneumonia</i> (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)	2
4	Fig. S4 — Antibacterial activity of compound (a) 1, 2, 3, 4; (b) 5, 6, 7, 8; (c) 9,10,11 and +ve control against <i>Staphylococcus aureus</i> (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)	3
5	Fig. S5 — ¹³ C NMR spectrum of compound R-1	3
6	Fig. S6 — ¹ H NMR spectrum of compound R-1	4
7	Fig. S7 — ¹³ C NMR spectrum of compound R-3	4
8	Fig. S8 — ¹ H NMR spectrum of compound R-8	5
9	Fig. S9 — ¹³ C NMR spectrum of compound R-8	5




Fig. S1 — Antibacterial activity of compound (a) 1, 2, 3, 4; (b) 5, 6, 7, 8 and (c) 9, 10, 11, +ve control against *Bacillus subtilis* (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)




Fig. S2 — Antibacterial activity of compound (a) 1, 2; (b) 3, 4; (c) 5, 6; (d) 7,8; (e) 9, 10, 11 and +ve control against *Escherichia coli* (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)




Fig. S3 — Antibacterial activity of compound (a) 1,2,3,4; (b) 5, 6, 7, 8 and (c) 9, 10, 11 +ve control against *Klebsiella pneumoniae* (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)




Fig. S4 — Antibacterial activity of compound (a) 1, 2, 3, 4; (b) 5, 6, 7, 8; (c) 9,10,11 and +ve control against *Staphylococcus aureus* (Compound 1=3a; 2=3b; 3=3c; 4=3d; 5=3e; 6=3f; 7=3g; 8=3h; 9=3i; 10=3j; 11=3k; +ve control= streptomycin)




Fig. S5 — ^{13}C NMR spectrum of compound R-1




Fig. S6 — ¹H NMR spectrum of compound R-1




Fig. S7 — ¹³C NMR spectrum of compound R-3

1H R-8, MeOD4, 29/05/17, SAIF, NEHU




Fig. S8 — ¹H NMR spectrum of compound R-8

¹³C R-8, MeOD4, 29/05/17, SAIF, NEHU




Fig. S9 — ¹³C NMR spectrum of compound R-8